Physician profile
Ashwin Dixit
NPI 1699736215
$2,676.88
in general payments reported to CMS, 2019-2025
25 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $179 · 2021: $490 · 2022: $546 · 2023: $357 · 2024: $400 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Education: $82.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.73 |
| Education | $82.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $375.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $322.41 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $281.46 | 2019-2024 | Tavneos, Aranesp, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $257.56 | 2019-2025 | Jynarque |
| Janssen Pharmaceuticals, INC | $243.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.54 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $129.91 | 2019-2025 | Rayaldee |
| Genzyme Corporation | $118.30 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $98.60 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $89.14 | 2020-2023 | Acthar |
| Travere Therapeutics, INC. | $74.79 | 2025 | |
| Akebia Therapeutics INC | $61.14 | 2019 | |
| Alexion Pharmaceuticals, INC. | $59.60 | 2019-2023 | Ultomiris |
| Scpharmaceuticals INC. | $56.63 | 2024 | |
| Novartis Pharmaceuticals Corporation | $56.56 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $55.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.14 | 2021-2023 | Gattex |
| Glaxosmithkline, LLC. | $39.01 | 2023-2025 | Arexvy, Benlysta |
| Fresenius USA Marketing, INC. | $33.07 | 2021-2022 | |
| Vantive US Healthcare LLC | $32.10 | 2025 | Renal - Pd |
| Alnylam Pharmaceuticals INC. | $24.11 | 2023 | Oxlumo |
| Aurinia Pharma U.S., INC. | $20.67 | 2025 | Lupkynis |
| Pfizer INC. | $20.06 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $18.33 | 2021 | |
| Mallinckrodt Enterprises LLC | $16.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.